Incyte (INCY) Tops Q3 EPS by 33c; Jakafi Sales Up 63%

Incyte (NASDAQ: INCY) reported Q3 EPS of $0.33, $0.33 better than the analyst estimate of $0.00. Revenue for the quarter came in at $198.15 million versus the consensus estimate of $149.92 million.

$97.8 million of 2014 third-quarter net product revenues from Jakafi® (ruxolitinib), representing 63 percent growth over the same period last year

2014 guidance for Jakafi net product revenues increased to range of $350 million to $360 million, driven by continued strong growth in underlying demand.

“The strong commercial performance of Jakafi in the U.S. speaks to the long-term potential of the product to treat patients with intermediate or high-risk myelofibrosis,” stated Hervé Hoppenot, Incyte’s President and Chief Executive Officer. “In addition, we believe we are fully prepared for the U.S. launch of ruxolitinib for patients with uncontrolled polycythemia vera, pending expected FDA approval, and are also making progress across our broad development pipeline.”

For earnings history and earnings-related data on Incyte (INCY) click here.

You May Also Be Interested In

• Tesla touts acceleration of new models, but Q1 results fall short of estimates
• IDEX Corp. (IEX) Tops Q1 EPS by 13c ; Offers Guidance
• Veralto Corporation (VLTO) Tops Q1 EPS by 6c, Offers Guidance